Cefozopran

Synonyms: 头孢唑兰; SCE-2787
Cefozopran (SCE-2787) 是一种具有广谱抗菌活性的强效抗生素,可结合 PBPs,诱导细胞壁破坏、细胞伸长、丝状体形成、不规则隔膜形成以及杀菌、溶菌活性,并能降低小鼠呼吸道、泌尿道和大腿肌肉感染模型中的细菌数量并清除细菌,可用于细菌感染的相关研究。
产品编号: MS-H20811 CAS No.: 113359-04-9 分子式: C19H17N9O5S2 分子量: 515.53
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Cefozopran (SCE-2787) 是一种具有广谱抗菌活性的强效抗生素,可结合 PBPs,诱导细胞壁破坏、细胞伸长、丝状体形成、不规则隔膜形成以及杀菌、溶菌活性,并能降低小鼠呼吸道、泌尿道和大腿肌肉感染模型中的细菌数量并清除细菌,可用于细菌感染的相关研究。

生物实验数据

生物活性 Cefozopran (SCE-2787) is a potent antibiotic with broad-spectrum antibacterial activity that binds PBPs to induce cell wall disruption, cell elongation, filamentous formation, irregular septum formation, and bactericidal and lytic activities, reduces and eradicates bacterial counts in mouse models of respiratory tract, urinary tract, and thigh muscle infections, and can be used for research related to bacterial infections.
IC50 & Target

β-lactam

 

体外研究
(In Vitro)

Cefozopran (20 h) 可强效抑制化脓性链球菌 (Streptococcus pyogenes)、金黄色葡萄球菌 (Staphylococcus aureus)、粪肠球菌 (Enterococcus faecalis) 的生长,且对链球菌属 (Streptococcus species)、肠杆菌科 (普通变形杆菌 Proteus vulgaris 除外) 以及甲氧西林 (MS-B49882) 敏感葡萄球菌表现出尤为显著的活性。
Cefozopran (20 h) 可抑制多种实验室需氧菌株的生长,其 MIC 值范围为 0.1 μg/mL 至 50 μg/mL,且对受试厌氧菌株的活性有限。
Cefozopran (20 h) 对头孢他啶 (MS-G66421) 耐药的弗氏柠檬酸杆菌 (MIC90 = 3.13 μg/mL) 和阴沟肠杆菌 (MIC90 = 12.5 μg/mL) 具有高活性,但对 Ceftazidime (MS-G66421) 耐药的铜绿假单胞菌 (MIC90 >100 μg/mL) 表现出与头孢他啶的交叉耐药性。
Cefozopran (200 μM) 对多数常见 β-内酰胺酶的水解作用具有高度抗性,包括 Bush 1、2a、2b 和 2c 组酶,但会被 Bush 2b'、2d 和 2e 组酶不同程度地水解。
Cefozopran 对所有受试 β-内酰胺酶的亲和力较低,其 Km/Ki 值均 >100 μM,表明它与这些酶的相互作用极弱。

体内研究
(In Vivo)

Cefozopran (5-80 mg/kg;皮下注射;每日 2 次;连续 5 天) 对小鼠急性 K. pneumoniae 呼吸道感染表现出强效活性。
Cefozopran (20-80 mg/kg;皮下注射;每日 2 次;共 7 天) 可有效清除小鼠体内慢性肺炎克雷伯菌呼吸道感染。
Cefozopran (1.56-100 mg/kg;皮下注射;每日 2 次;连续 5 天;感染后 3 天开始) 对小鼠 P. aeruginosa 尿路感染表现出强效抑制活性。
Cefozopran (0.625-40 mg/kg;皮下注射;感染后 2、18、26 小时给药) 对小鼠 MSSA 大腿肌肉脓肿感染显示出强效作用。

Animal Model: ICR mice (4-week-old, male) with acute respiratory tract infection induced by aerosol exposure to Klebsiella pneumoniae DT-S for 40 minutes
Dosage: 5; 20; 80 mg/kg
Administration: s.c.; twice daily; 5 days
Result: Showed 0/10 survival rate and 0/10 lung sterilization rate at 5 mg/kg.
Showed 8/10 survival rate and 2/10 lung sterilization rate at 20 mg/kg.
Showed 10/10 survival rate and 10/10 lung sterilization rate at 80 mg/kg.
Achieved an SD50 of 13.8 mg/kg and a CD50 of 29.0 mg/kg.
Had an MIC of 0.05 μg/mL against Klebsiella pneumoniae DT-S.
Animal Model: CBA/J mice (5-week-old, female) with chronic respiratory tract infection induced by aerosol exposure to Klebsiella pneumoniae 27 for 60 minutes
Dosage: 20; 40; 80 mg/kg
Administration: s.c.; twice daily; 7 days
Result: Showed 1/12 lung sterilization rate at 20 mg/kg.
Showed 0/11 lung sterilization rate at 40 mg/kg.
Showed 12/12 lung sterilization rate at 80 mg/kg.
Achieved a CD50 of 55.2 mg/kg.
Had an MIC of 0.05 μg/mL against Klebsiella pneumoniae 27.
Animal Model: CBA/J mice with urinary tract infection induced by transurethral inoculation of Pseudomonas aeruginosa P9 with urethral clamping for 6 hours
Dosage: 1.56; 6.25; 25; 100 mg/kg
Administration: s.c.; twice daily; 5 days; tarting 3 days after infection
Result: Showed 3/15 kidney sterilization rate at 1.56 mg/kg.
Showed 7/15 kidney sterilization rate at 6.25 mg/kg.
Showed 11/15 kidney sterilization rate at 25 mg/kg.
Showed 12/15 kidney sterilization rate at 100 mg/kg.
Achieved a CD50 of 8.78 mg/kg.
Had an MIC of 0.78 μg/mL against Pseudomonas aeruginosa P9.
Animal Model: ICR mice with thigh muscle infection induced by injection of Methicillin-sensitive Staphylococcus aureus
Dosage: 0.625; 2.5; 10; 40 mg/kg
Administration: s.c.; single dose at 2, 18, 26 hours post-infection
Result: Showed a mean bacterial count of 6.14 log CFU and an effective rate of 2/8 at 0.625 mg/kg.
Showed a mean bacterial count of 5.38 log CFU and an effective rate of 3/8 at 2.5 mg/kg.
Showed a mean bacterial count of 4.77 log CFU and an effective rate of 6/8 at 10 mg/kg.
Showed a mean bacterial count of 4.59 log CFU and an effective rate of 8/8 at 40 mg/kg.
Achieved an ED50 of 2.87 mg/kg.
Had an MIC of 0.39 μg/mL against methicillin-sensitive Staphylococcus aureus.
Animal Model: ICR mice with thigh muscle infection induced by injection of Methicillin-resistant Staphylococcus aureus N133
Dosage: 3.125; 12.5; 50; 200 mg/kg
Administration: s.c.; single dose at 2, 18, 26 hours post-infection
Result: Showed a mean bacterial count of 7.63 log CFU and an effective rate of 0/8 at 3.125 mg/kg.
Showed a mean bacterial count of 7.55 log CFU and an effective rate of 0/8 at 12.5 mg/kg.
Showed a mean bacterial count of 6.54 log CFU and an effective rate of 2/8 at 50 mg/kg.
Showed a mean bacterial count of 4.82 log CFU and an effective rate of 7/8 at 200 mg/kg.
Achieved an ED50 of 79.8 mg/kg.
Had an MIC of 50 μg/mL against methicillin-resistant Staphylococcus aureus N133.

化学信息

分子量 515.53
分子式 C19H17N9O5S2
CAS No. 113359-04-9
别名 头孢唑兰; SCE-2787

储存&溶解度

溶解度信息
DMSO: Soluble
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础